Global Peripheral T-Cell Lymphoma (PTCL) Market Spotlight 2018-2026

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Peripheral T-Cell Lymphoma (PTCL)” report has been
added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Peripheral T-Cell Lymphoma
market, comprising key marketed and pipeline drugs, clinical trials,
upcoming events, probability of success, patent information, a 10-year
disease incidence forecast, and licensing and acquisition deals, as well
as presenting drug-specific revenue forecasts

Key Takeaways

• The author estimates that in 2017, there were approximately 19,950
  incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
  forecasts that number to increase to 23,880 incident cases by 2026.
• It is estimated that the majority of diagnosed cases were in males in
  2017.
• The incidence of PTCL is highest among older individuals aged 60+
  years. The approved drugs in the PTCL space focus on a wide variety of
  targets. These drugs are administered via the intravenous and oral
  routes.
• The majority of industry-sponsored drugs in active clinical
  development for PTCL are in Phase II, with only one drug in Phase III.
  Therapies in the pipeline for PTCL focus on a wide variety of targets.
  The majority of pipeline drugs in development are administered
  intravenously, with a smaller number being tested in oral formulations.
• High-impact upcoming events for drugs in the PTCL space comprise
  topline Phase II trial results for Darzalex and Zinapar. The overall
  likelihood of approval of a Phase I hematologic asset is 10.7%, and
  the average probability a drug advances from Phase III is 57.6%.
  Drugs, on average, take 8.7 years from Phase I to approval, compared
  to 9.2 years in the overall oncology space.
• There have been 14 licensing and asset acquisition deals involving
  PTCL drugs during 2013-18. The $190m exclusive licensing agreement
  signed in October 2017 between Karyopharm and Ono Pharmaceutical for
  the development and marketing of Karyopharm’s selinexor and KPT-8602
  in South Korea, Hong Kong, Taiwan, Japan, and ASEAN countries was the
  largest deal during the period.
• The clinical trials distribution across Phase I-IV indicates that the
  vast majority of trials for PTCL have been in the early and midphases
  of development, with 93% of trials in Phase I-II, and only 7% in Phase
  III-IV.
• The US has a substantial lead in the number of PTCL clinical trials
  globally. The UK leads the major EU markets, while Japan has the top
  spot in Asia.
• Clinical trial activity in the PTCL space is dominated by completed
  trials. Celgene has the highest number of completed clinical trials
  for PTCL, with nine trials.
• Celgene leads industry sponsors with the highest number of clinical
  trials for PTCL, followed by Spectrum Pharmaceuticals.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

Approvals by country

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Adcetris for PTCL (October 1, 2018)

Cerdulatinib for PTCL (June 4, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Adcetris Speeds To PTCL Approval With Two-Week Review

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Onxeo Seeks Partner For Its Expanding Oncology Pipeline

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/o7o429

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematology